– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – –. | June 10, 2023
13.04.2023 - Presentations highlight data from across all oncology pipeline programsMOUNTAIN VIEW, Calif., April 13, 2023 (GLOBE NEWSWIRE) - IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing . Seite 1
Operator: Good day, everyone, and welcome to the IGM Biosciences Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. Today s call is being recorded.
IGM Biosciences (IGMS) Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
09.01.2023 - – Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients – – Encouraging safety profile in combination with FOLFIRI chemotherapy – – Randomized combination trial in . Seite 1
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL –– Phase 1 Trial Expected to be Initiated in 1Q23 –MOUNTAIN VIEW, Calif. & LAUSANNE, Switzerland (BUSINESS WIRE) IGM Biosciences, Inc. (Nasdaq:.